Published online before print April 10, 2008, doi: 10.1161/STROKEAHA.107.506378
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2008;39:1774.)
© 2008 American Heart Association, Inc.
Original Contributions |
DP-b99, a Membrane-Activated Metal Ion Chelator, as Neuroprotective Therapy in Ischemic Stroke
From the Department of Neurology (H.C.D.), University of Duisburg-Essen, Essen, Germany; Neurologic ICU and Stroke Unit (D.S.), University of Leipzig, Leipzig, Germany; Department of Neurology (Y.L.), Edith Wolfson Medical Center, Holon and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Neurology (N.M.B.), Tel Aviv Medical Center and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; and D-Pharm Ltd (A.K., G.R.), Rehovot, Israel.
Correspondence to Prof Dr Hans-Christoph Diener, Department of Neurology, University Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany. E-mail hans.diener{at}uni-duisburg-essen.de
Background and Purpose— DP-b99 is a chelator of zinc and calcium ions that acts selectively within cell membranes and has neuroprotective properties in animal models of stroke. We present the results of a multicenter, double-blind, placebo-controlled, randomized trial to assess the safety and potential protective effects of DP-b99 in acute ischemic stroke.
Methods— One hundred and fifty stroke patients with signs of cortical involvement and a National Institutes of Health Stroke Scale (NIHSS) score of 7 to 20 received a 4-day course of intravenous 1 mg/kg per day DP-b99 or placebo within 1 to 9 hours of stroke onset. Treatment with recombinant tissue plasminogen activator was not allowed.
Results— No major differences in mortality rate, causes of death, adverse events, safety laboratory tests, and ECG parameters were found between the 2 groups. The baseline NIHSS score of the 72 DP-b99– and 75 placebo-treated patients in the intent-to-treat cohort was (mean±SD) 12.2±4.0 and 12.6±3.3, respectively; the time to needle (mean±SD) was 6:36±1:47 and 6:28±1:33 hours, respectively; and the age (mean±SD) was 73.3±9.9 and 72.0±9.6 years, respectively. The 90-day median change from baseline (the primary end point) was –6.0 and –5.0 NIHSS points in the DP-b99 and placebo groups, respectively (nonsignificant). At 90 days, there was a significantly better outcome in the DP-b99 group compared with the placebo group (modified Rankin scale score of 0, 1, or same as prestroke): 30.6% and 16.0%, respectively (P=0.05). The recovery rate was unaffected by the time to needle. Further analyses indicated that the 90-day median change from baseline in patients with an entry NIHSS score of 10 to 16 was 8.0 and 5.0 points in the DP-b99 and placebo groups, respectively (P=0.03).
Conclusions— In this small-scale study, the primary end point of change in NIHSS score from baseline to 90 days was not met. However, secondary end points demonstrated a significantly improved 90-day recovery rate with treatment with DP-b99 when compared with placebo. In addition, in patients with baseline NIHSS scores of 10 to 16, a significant post hoc change in NIHSS score from baseline to day 90 was observed. No major safety problems were identified. These findings need to be confirmed with a larger prospective study of strokes involving the cortex.
Key Words: ischemic stroke • neuroprotective therapy • membrane-activated metal ion chelator • randomized trials • placebo-controlled studies
This article has been cited by other articles:
 |
|
 |
|
  H. Ehrenreich, K. Weissenborn, H. Prange, D. Schneider, C. Weimar, K. Wartenberg, P. D. Schellinger, M. Bohn, H. Becker, M. Wegrzyn, et al. Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke Stroke, December 1, 2009; 40(12): e647 - e656. [Abstract] [Full Text] [PDF]
|
|